This happens to most people
You're Not Alone
Getting denied doesn't mean the answer is no forever. It means the insurer needs more information — or you need to push back. The majority of people who appeal with proper documentation get approved. (Success rates vary by denial type and documentation quality.)
Find your denial reason below
Why Were You Denied?
Your denial letter should state the reason. Click the one that matches — each has a different appeal strategy:
Medical Necessity
"Not medically necessary" or "doesn't meet clinical criteria"
See how to appeal →Step Therapy
"Must try other medications first" or "preferred alternative available"
See how to appeal →Formulary Exclusion
"Not covered under your plan" or "excluded medication"
See how to appeal →BMI / Criteria
"Does not meet BMI requirements" or "missing documentation"
See how to appeal →Not Sure / Other
Don't see your reason? Start here for general guidance.
Full appeals guide →What Insurers Look For in Approvals
- BMI documentation — Recent measurements (ideally <6 months)
- Comorbidity codes — Type 2 diabetes, hypertension, sleep apnea, cardiovascular disease, etc.
- Prior medication history — What you've tried before and why it failed
- Lifestyle modification proof — Diet/exercise programs, dietitian visits
- Physician letter of medical necessity — Explaining why Wegovy specifically
Missing any of these is a common reason for denial. Your appeal should address the gap.
3 immediate steps
What to Do Right Now
Find Your Denial Letter
Look for the specific reason they denied you. It's usually in a paragraph that starts with "Your request was denied because..." This determines your appeal strategy.
Note Your Deadline
You have 180 days from the denial date to file an internal appeal (under most plans). Missing this deadline typically forfeits your right to appeal. Mark it on your calendar.
Start Your Appeal
Honest Care writes your personalized appeal letter for free. We'll ask a few questions about your situation and denial, then create an insurer-ready letter.
Get Free Appeal Letter →Need Wegovy while your appeal is processing? NovoCare offers self-pay options starting at $199/month for the first two fills, then $349/month — significantly lower than retail pricing of ~$1,349/month.
Wegovy-Specific Options
- Cardiovascular coverage pathway: If you have established cardiovascular disease and either obesity or overweight, Wegovy may be covered for cardiovascular risk reduction (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets)) even if weight loss is excluded.
- Oral Wegovy: The new Wegovy pill (FDA-approved December 2025) may have different formulary status than the injection.
- Diabetes pathway: If you have Type 2 diabetes, Ozempic (same active ingredient as Wegovy) may be covered for diabetes.
The numbers are on your side
Appeals Actually Work
Many insurers expect patients not to appeal — which is why taking action matters. The appeal process exists for a reason, and it often works.
Step-by-step process, strategies, and documentation checklist
Worth every penny
When I received my denial letter from my insurance I was devastated and started searching how to write an appeal letter. I came across Honest Care in a group chat and I'm so happy I did. After answeri...
Very happy with Honest Care
Very happy with Honest Care. They delivered my letter in timely manner and had phone call very next day with them to finish and update letter with additional information. Sent to Insurance with record...
Helped me in the 11th hour
I am so grateful for Honest Care's services. They helped me out in the 11th hour. After doing hours of online research and written 5 or more drafts of an appeal letter, I felt deflated and exhausted t...
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get startedCommon questions after a denial
Quick Answers
Yes. You have several options: (1) Appeal the denial — 65%+ of appeals succeed with proper documentation. (2) Pay cash — NovoCare offers Wegovy starting at $199/month (see current pricing). (3) Try a different pathway — If you have established cardiovascular disease and obesity or overweight, Wegovy may be covered for cardiovascular risk reduction even if weight loss is excluded. If you have diabetes, Ozempic (same ingredient) may be covered.
You typically have 180 days from the date on your denial letter to file an internal appeal (check your plan documents for exact deadlines). After that, you may lose your right to appeal. Mark your calendar and don't wait.
Good. 65%+ of appeals succeed when you have proper documentation (AMA/KFF data). The key is addressing the specific reason you were denied and providing the right evidence.
Yes. NovoCare offers Wegovy at reduced self-pay prices — $199/month for the first two fills (0.25 mg and 0.5 mg), through December 31, 2026, then $349/month ($399 for Wegovy HD 7.2 mg) (see current pricing). This lets you start treatment while your appeal is pending. If your appeal succeeds, some plans may reimburse part of your out-of-pocket costs.
It can be. The FDA approved Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets)). This is separate from the weight-loss indication and may have different coverage. If your plan excludes weight-loss drugs but you have established cardiovascular disease, ask your doctor about the CV indication pathway.
The oral Wegovy (semaglutide tablet) was FDA-approved in December 2025. It may have different formulary placement than the injection at some insurers. Check with your plan or learn more about oral Wegovy.
WHAT'S CHANGING
Wegovy Denials: 2026 Outlook
2026: Mixed Outlook for Coverage
While more employers are adding GLP-1 coverage (estimated 25%+ in 2026, up from 19%), denial rates remain high due to stricter PA requirements and cost management strategies. California Medi-Cal ended Wegovy weight-loss coverage on January 1, 2026, though coverage continues for diabetes and cardiovascular indications.
CMS Prior Authorization Reform
The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) takes effect in 2026:
- Faster decisions: From January 1, 2026, Medicare Advantage, Medicaid and CHIP must decide medical prior authorizations within 7 days (72 hours if urgent); the rule excludes drugs (so it doesn't change Wegovy prior authorization timelines)
- Transparency: Insurers must disclose denial reasons clearly
- Digital integration: PA requests through electronic health records
If Appeals Fail: Self-Pay Options
For patients who exhaust appeal options, NovoCare offers Wegovy at reduced self-pay prices:
- Injectable: $199/month for the first two fills (0.25 mg and 0.5 mg), through December 31, 2026, then $349/month ($399 for Wegovy HD 7.2 mg) (vs $1,349/month list price)
- Oral pill: $149–$299/month (launched January 5, 2026)
Wegovy's Cardiovascular Advantage
Unlike other GLP-1s approved for weight management, Wegovy has FDA approval for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets); based on the SELECT trial showing 20% reduction in heart attacks, strokes, and CV death). This creates an alternative coverage pathway:
- CV indication: May be covered even when weight loss is excluded
- Medicare potential: for the CV indication, Wegovy may be covered under Part D, subject to the plan’s formulary, prior authorization and exceptions process (basic Part D excludes weight-loss drugs; the Medicare GLP-1 Bridge is separate)
Denied Another GLP-1?
Appeal strategies are similar across GLP-1 medications:
References
- IvyRx. "Wegovy Requirements For Insurance Coverage Explained (2026)." January 2026. ivyrx.com
- Health System Tracker / KFF. "Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss." October 2025. healthsystemtracker.org
- American Medical Association / Kaiser Family Foundation. Prior authorization appeal success data. Note: AMA reports 80%+ for Medicare Advantage; we use a conservative 65%+ estimate for commercial insurance plans. ama-assn.org
- Kaiser Family Foundation. "Claims Denials and Appeals in ACA Marketplace Plans." KFF Analysis, 2023. kff.org
- FDA. "FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight." March 8, 2024. fda.gov
- California Department of Health Care Services. "Medi-Cal Rx State Budget Policy Updates." December 2025. medi-calrx.dhcs.ca.gov
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.